Thermosome Appoints Dr. Sabine Hauck as Chief Technical Officer
11. Juni 2024 04:00 ET
|
AKAMPION
- Experienced biopharma professional focused on drug product development Munich, Germany - June 11, 2024 - Thermosome, a drug development company focused on targeted tumor therapies, today...
Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001
06. Februar 2024 04:00 ET
|
AKAMPION
- First dose level rated as safe by independent Data Safety Monitoring Board- Second dose level to be administered according to plan- THE001 designed as targeted tumor treatment independent...
Thermosome Establishes High-Profile Clinical Advisory Board
19. September 2023 04:00 ET
|
AKAMPION
Leveraging the transformative potential of TSL-based tumor targeting Supporting the progress of Thermosome's clinical candidate THE001 Munich, Germany – September 19, 2023 – Thermosome, a drug...
Soft Tissue Sarcoma Market to Propel by 2032, Predicts DelveInsight | Key Companies in the Market - Monopar, Jazz, Tracon, C4, Eli Lilly, Epizyme, Ipsen, GlaxoSmithKline, Salarius, Merck, Agenus, Mirati
03. August 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Soft Tissue Sarcoma Market to Propel by 2032, Predicts DelveInsight | Key Companies in the Market - Monopar, Jazz, Tracon, C4, Eli Lilly, Epizyme,...
Thermosome Announces Participation in IMAGIO Consortium to Improve Cancer Treatment
20. Juni 2023 04:00 ET
|
AKAMPION
IMAGIO consortium of clinical partners coordinated by Philips receives EUR 24 million grant from the Innovative Health Initiative (IHI) and additional funding from industry partners to support the...
Thermosome Announces First Patient Dosed in Phase I Trial with Lead Program THE001
24. Mai 2023 04:00 ET
|
AKAMPION
- Addressing high unmet medical need in locally advanced soft tissue sarcoma- Targeted tumor treatment independent of specific molecular targets or tumor subtypes Munich, Germany – May 24,...
Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001
28. März 2023 03:45 ET
|
AKAMPION
- Novel compound for targeted tumor therapy to be evaluated in patients with soft tissue sarcoma- First patients to be enrolled in Q2, 2023 Munich, Germany – March 28, 2023 – Thermosome, a...
Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
27. Oktober 2021 08:05 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Philogen Provides Corporate Update
29. September 2021 04:58 ET
|
Philogen
Philogen Provides Corporate Update Nidlegy™ and Fibromun on track with planned timelines in pivotal clinical trialsUse of Nidlegy™ in non-melanoma skin cancer expanded in Phase II clinical...
The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030, growing at an annualized rate of 27.54% during the period 2021-2030, claims Roots Analysis
22. September 2021 09:00 ET
|
Roots Analysis
London, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Soft Tissue Sarcoma Market: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report...